Avant Technologies and SGAustria Launch Joint Venture to Develop Stem Cell-Based Diabetes Therapy
核心洞察
Avant Technologies (搜索) and SGAustria (搜索) have formed a joint venture called Insulinova (搜索) to develop diabetes (搜索) therapies using stem cell and encapsulation technologies targeting type 1 and insulin-dependent type 2 diabetes (搜索).
The partnership combines a proprietary differentiation process that converts stem cells into insulin-producing cells with SGAustria (搜索)'s cell-encapsulation platform based on over 50 peer-reviewed studies.
Avant will provide initial funding over eight months to establish reproducible diabetes (搜索) therapy criteria and seek additional funding to progress toward a potential Phase I clinical trial in the US.
Avant Technologies (搜索) and SGAustria (搜索) have announced a joint venture and licensing agreement to advance innovative diabetes (搜索) therapies using stem cell and encapsulation technologies, establishing a new US-based company called Insulinova (搜索) to facilitate clinical development.
Partnership Targets Critical Diabetes Treatment Gap
The collaboration focuses on developing treatments for type 1 diabetes (搜索) and some insulin-dependent type 2 diabetes (搜索) cases through a proprietary differentiation process that converts stem cells into insulin-producing cells. This approach will be advanced through a research collaboration agreement (RCA) that combines stem cell expertise with SGAustria (搜索)'s established encapsulation platform.
The joint venture encompasses the research, development, manufacture and marketing of diabetes (搜索) therapies utilizing encapsulated stem cells before, during, or after differentiation. By merging these technologies, the companies aim to produce scalable and safe solutions for global distribution.
Technology Platform and Scientific Foundation
SGAustria (搜索) contributes its cell-encapsulation technology, which is supported by over 50 peer-reviewed studies and collaborations with global biotech firms. This platform is designed to transport, protect, isolate, and store living cells, providing a critical foundation for the therapeutic approach.
"SGAustria (搜索)'s encapsulation platform holds tremendous promise for reshaping cell therapies, and this JV stands as proof of that potential," said SGAustria CEO Brian Salmons. "Teaming up with Avant and a prospective RCA partner allows us to leverage our combined capabilities to deliver cutting-edge, reliable diabetes (搜索) treatments, supported by our established proficiency in GMP production and cellular science."
Funding and Clinical Development Timeline
Avant Technologies (搜索) will provide initial funding during the upcoming eight months to meet criteria for establishing a reproducible diabetes (搜索) therapy. The company plans to seek additional funding to progress toward a potential Phase I trial in the US or equivalent jurisdiction.
"We're thrilled to join forces with SGAustria (搜索) in this game-changing JV," said Avant Technologies (搜索) CEO Chris Winter. "Merging our capital and forward-thinking strategy with their advanced biotech innovations, we're setting the stage for revolutionary diabetes (搜索) therapies that have the potential to transform countless lives."
Strategic Structure and Future Development
Under the agreement structure, SGAustria (搜索) holds an exclusive license and may secure a future license contingent on RCA completion. This licensing framework positions the joint venture to address what the companies describe as a critical health challenge in diabetes (搜索) treatment.
The establishment of Insulinova (搜索) as a US-based entity is specifically designed to facilitate clinical trials and advance the therapeutic development process within the American regulatory framework.